Yekkirala Ajay S, Kalyuzhny Alexander E, Portoghese Philip S
Department of Medicinal Chemistry, College of Pharmacy, ‡Department of Pharmacology, and §Department of Neuroscience, Medical School, University of Minnesota, Minneapolis, Minnesota 55455, United States.
ACS Chem Biol. 2013 Jul 19;8(7):1412-6. doi: 10.1021/cb400113d. Epub 2013 May 17.
Bivalent ligands that contain two pharmacophores linked by a spacer are promising tools to investigate the pharmacology of opioid receptor heteromers. Evidence for occupation of neighboring protomers by two phamacophores of a single bivalent ligand (bridging) has relied mainly on pharmacological data. In the present study, we have employed an immunocytochemical correlate to support in vivo biological studies that are consistent with bridging. We show that a bivalent mu agonist/delta antagonist (MDAN-21) that is devoid of tolerance due to possible bridging of mu and delta protomers prevents endocytosis of the heteromeric receptors in HEK-293 cells. Conversely, a bivalent ligand (MDAN-16) with a short spacer or monovalent mu agonist give rise to robust internalization. The data suggest that the immobilization of proximal mu and delta protomers is due to bridging by MDAN-21. The finding that MDAN-21 and its shorter spacer homologue MDAN-16 possess equivalent activity in HEK-293 cells, but produce dramatically divergent internalization of mu-delta heteromer, is relevant to the role of internalization and tolerance.
含有通过间隔基团连接的两个药效基团的双价配体是研究阿片受体异聚体药理学的有前景的工具。单个双价配体的两个药效基团占据相邻原体(桥接)的证据主要依赖于药理学数据。在本研究中,我们采用了一种免疫细胞化学相关方法来支持与桥接一致的体内生物学研究。我们表明,一种由于μ和δ原体可能的桥接而无耐受性的双价μ激动剂/δ拮抗剂(MDAN - 21)可防止HEK - 293细胞中异聚体受体的内吞作用。相反,具有短间隔基团的双价配体(MDAN - 16)或单价μ激动剂会导致强烈的内化。数据表明,近端μ和δ原体的固定是由于MDAN - 21的桥接。MDAN - 21及其较短间隔基团同系物MDAN - 16在HEK - 293细胞中具有等效活性,但产生μ - δ异聚体的内化差异巨大,这一发现与内化和耐受性的作用相关。